目的 分析美罗培南致血小板计数异常（增多或减少）的发生特点，为临床合理用药提供参考。方法 检索PubMed、Embase、MedLine、Research Gate、中国知网、万方数据库和维普数据库，时间截止至2022年5月，纳入美罗培南致血小板计数异常的中英文病例报道，对文献进行筛选、数据归纳及统计。结果 最终纳入22例患者，其中男性13例，女性9例；年龄0.5～96岁，平均（59.98±25.34）岁；14例患者患有基础疾病，15例患者为联合用药。引起血小板计数增多症患者9例（40.91%），血小板计数减少症患者13例（59.09%），所有患者血小板计数异常均发生在用药期间。停用美罗培南并给予对症处理后，21例（95.45%）患者血小板计数恢复正常或好转。结论 美罗培南致血小板计数异常以血小板减少症相对多见。临床在使用美罗培南期间应加强对血小板计数的监测，一旦发现异常变化应及时停药和对症处理，减少血栓或出血事件的发生。

Objective To analyze the characteristics of abnormal platelet count (increase or decrease) caused by meropenem, and to provide references for rational drug use in clinic. Methods The Pubmed, Embase, Medline, Research Gate, CNKI, Wanfang, and VIP database were searched until May 2022. Both Chinese and English case reports of platelet count abnormalities caused by meropenem were included, and the data were extracted and analyzed. Results 22 Patients were included, including 13 males and 9 females. The age ranged from 0.5 to 96 years, and the overall mean age was (59.98 ±25.34) years. 14 patients suffered from basic diseases, and 15 patients were treated with combination therapy. 9 Patients (40.91%) with thrombocytopenia and 13 patients (59.09%) with thrombocytopenia, all patients had abnormal platelet count during medication. After discontinuation of meropenem and symptomatic treatment, platelet count returned to normal or improved in 21 patients (95.45%). Conclusion Thrombocytopenia is more common than thrombocythemia. During the clinical use of meropenem, the monitoring of platelet count should be strengthened. Once abnormal changes are found, the drug should be stopped in time and symptomatic treatment should be given to reduce the occurrence of thrombosis or bleeding events.

R978.1